Scribe Therapeutics Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Vol. 1Y

—

Shs. 5Y

—

Rev. 5Y

Div Yld LY

—

Div Yld TTM

—

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Key people

Benjamin Oakes

President, Chief Executive Officer, Co-Founder, Director · since 2020

Jennifer Doudna

Co-Founder, Scientific Advisor

David Savage

Co-Founder, Scientific Advisor

David Parrot

Chief Financial Officer · since 2021

Brett Staahl

Co-Founder, Vice President - External Innovation · since 2022

Svetlana Lucas

Chief Business Officer

URL

https://www.scribetx.com

IPO date

Jul 24, 2026

Employees

Domiciled in

Incorporated in

Valuation

No data to show